Home > Insider Trading > Filing (0000899243-16-028321)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1609809	Seres Therapeutics Inc.	MCRB	Pharmaceutical Preparations (2834)	274326290

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1643756	G. John Aunins	C/O Seres Therapeutics, Inc. 215 First Street Cambridge MA 02142	Chief Technology Officer & Evp	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2016-04-25	18,640	$31.94	56,060	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct

Footnotes

This line item is not new or revised, but is being reported again solely to gain access to the electronic filing system for filing this amendment. This Form 4 when it was initially filed by the Reporting Person on April 27, 2016 and four Forms 4 filed by the Reporting Person after that date incorrectly stated the date the Reporting Person adopted his 10b5-1 trading plan. This amendment is being filed to correct such date.
The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 26, 2016.
The price reported is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $31.48 to $32.34. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.